– Solid yes for men and transgender women, but consensus missing for cisgender women

An FDA advisory panel overwhelmingly voted 16-2 to recommend Descovy, the fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF), as pre-exposure prophylaxis (PrEP) to reduce HIV acquisition in men who have sex with men (MSM) and transgender women.

But murmurs echoed throughout the room as the FDA’s Antimicrobial Drugs Advisory Committee split 8-10 on whether to recommend a PrEP indication for F/TAF in cisgender women. Read the entire article here